Alcresta Therapeutics Inc, a developer of enzyme-based products, has named Daniel Orlando as CEO and a member of its board of directors. Prior to joining Alcresta, Orlando was chief operating officer at Vericel Corporation. Alcresta is backed by Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners and Third Rock Ventures.
WARREN, N.J.–(BUSINESS WIRE)–Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Daniel Orlando as its Chief Executive Officer (CEO) and member of the Board of Directors effective June 17, 2019.
“On behalf of the board of directors, I am very pleased to welcome Daniel to Alcresta Therapeutics. Daniel is an accomplished leader with extensive knowledge of the global healthcare landscape. His deep understanding of commercialization, as well as strong clinical and regulatory insights will be of great value to Alcresta,” said Jeremy Lack, Partner at Athyrium Capital.
Mr. Orlando joins Alcresta with more than 18 years of experience in executive roles leading organizations through rapid growth while successfully developing and launching therapeutics and biologics. Prior to joining Alcresta, Daniel was Chief Operating Officer at Vericel Corporation, where during his tenure he led every function of the cell therapy company, most recently, the Commercial, Manufacturing, Engineering and R&D organizations. Previously, Mr. Orlando held executive positions in Business Development, Marketing and Sales with Takeda as well as similar developmental roles at Abbott Laboratories.
“I am excited to join Alcresta during this early stage of commercial growth. Its mission of helping enterally fed patients reach their potential during times of critical nutritional need is such compelling work.” Alcresta’s first-in-class enzyme-based RELiZORB product provides significant nutritional benefits for Orphan and Ultra-Orphan patient populations such as those with Cystic Fibrosis and Pancreatitis. “I look forward to working with the talented Alcresta team, our providers and patients to accelerate RELiZORB’s adoption and advance our promising R&D pipeline,” said Mr. Orlando.
About Alcresta® Therapeutics, Inc.
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta currently markets RELiZORB for enterally fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer and pancreatitis, and is developing platform applications for patients with short bowel syndrome (SBS) and prematurely born infants treated in the NICU. Alcresta Therapeutics, Inc. is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures. More information can be found at www.alcresta.com.